Vanda Pharmaceuticals Inc.
HealthcareNASDAQ:VNDA · NASDAQ Global Market
-$0.23 today
Vol 1.30M · Avg 1.34M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $54.0M |
| Short-term Investments | $148.3M |
| Receivables | $56.9M |
| Inventory | $1.7M |
| Other Current | $32.3M |
| Total Current Assets | $293.2M |
| PP&E (Net) | $14.1M |
| Intangible Assets | $115.1M |
| Other Non-current | $11.2M |
| Total Non-current Assets | $140.4M |
| Total Assets | $433.5M |
Analysis
Selected assets total $433.5M for Latest. The largest visible component is Short-term Investments at $148.3M, about 34.2% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $84.9M -17.1% | $102.3M -24.7% | $135.8M +0.6% | $135.0M +159.3% | $52.1M | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $179.0M -34.3% | $272.3M +7.9% | $252.4M -23.9% | $331.8M -12.8% | $380.7M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $54.6M +15.9% | $47.1M +37.9% | $34.2M +1.9% | $33.5M +3.2% | $32.5M | $533.8M | $399.4M | -$1.7B |
| Inventory | $1.9M +7.3% | $1.7M +27.2% | $1.4M +13.7% | $1.2M +16.5% | $1.0M | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $27.0M +75.0% | $15.4M +68.2% | $9.2M -48.3% | $17.7M | $0 | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $347.3M -20.9% | $438.9M +1.4% | $432.9M -16.6% | $519.3M +8.6% | $478.3M | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $13.5M +6.6% | $12.7M +38.7% | $9.1M -16.7% | $11.0M -11.4% | $12.4M | $1.2B | $1.5B | $687.8M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $117.1M +2.6% | $114.1M -6.0% | $121.4M +553.8% | $18.6M -7.5% | $20.1M | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $0 | $0 | $0 | $0 | $0 | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 -100.0% | $81.4M +8.6% | $75.0M +1.3% | $74.0M -1.1% | $74.9M | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $11.1M +21.8% | $9.1M -8.9% | $10.0M -12.2% | $11.4M +39.7% | $8.1M | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $141.7M -34.8% | $217.3M +0.8% | $215.5M +87.5% | $115.0M -0.5% | $115.5M | -$15.3B | $14.8B | $11.3B |
| Total Assets | $488.9M -25.5% | $656.2M +1.2% | $648.4M +2.2% | $634.2M +6.8% | $593.8M | $13.3B | $11.9B | $10.6B |
| Account Payables | $4.9M +41.2% | $3.5M -51.0% | $7.1M -43.7% | $12.7M +1271.9% | $925.0K | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $0 | $0 | $0 | $0 | $0 | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $0 | $0 | $0 | $0 | $0 | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $97.2M +40.1% | $69.4M +0.0% | $69.3M +103.9% | $34.0M +22.9% | $27.7M | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $145.2M +45.2% | $100.0M +14.0% | $87.7M -4.1% | $91.4M +22.9% | $74.4M | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $9.5M -0.6% | $9.6M +8.6% | $8.8M +29.8% | $6.8M +54.9% | $4.4M | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $16.6M -6.1% | $17.7M +11.6% | $15.8M +1.4% | $15.6M +8.1% | $14.4M | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $161.8M +37.5% | $117.7M +13.6% | $103.5M -3.3% | $107.0M +20.5% | $88.9M | $14.7B | $3.7B | $9.6B |
| Common Stock | $59.0K +1.7% | $58.0K +0.0% | $58.0K +1.8% | $57.0K +1.8% | $56.0K | $651.4M | $517.0M | $382.6M |
| Retained Earnings | -$394.8M -126.5% | -$174.3M -12.2% | -$155.4M +1.6% | -$157.9M +3.8% | -$164.2M | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | $629.0K +750.0% | $74.0K +346.7% | -$30.0K +97.5% | -$1.2M -581.7% | -$175.0K | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $1.4B | $337.8M | $931.4M |
| Total Equity | $327.2M -39.2% | $538.5M -1.2% | $544.9M +3.4% | $527.2M +4.4% | $504.9M | $9.1B | $7.7B | $3.3B |
| Total Debt | $12.6M +2.1% | $12.4M +31.4% | $9.4M -15.6% | $11.1M -9.9% | $12.4M | $724.2M | $410.6M | $399.4M |
| Net Debt | -$72.2M +19.7% | -$90.0M +28.8% | -$126.4M -2.0% | -$123.9M -212.0% | -$39.7M | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.18B
Achieve Life Sciences, Inc.
NASDAQ:ACHV
$566.68M
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$463.35M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$359.32M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$250.78M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$211.47M
Sagimet Biosciences Inc.
NASDAQ:SGMT
$211.13M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$198.11M
Humacyte, Inc.
NASDAQ:HUMA
$177.24M
Immuneering Corporation
NASDAQ:IMRX
$152.11M
SEC Filings
Recent regulatory filings
No filings found.
How much cash does VNDA have?
Vanda Pharmaceuticals Inc. (VNDA) reported $84.85M in cash and equivalents in fiscal 2025.
How much debt does VNDA carry?
Vanda Pharmaceuticals Inc. (VNDA) reported $12.62M of total debt, with net debt of -$72,229,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.